Sponsored
Evolving Dynamics in the HER2-Low Cancer Landscape: Market Outlook and Growth Potential
Introduction The recognition of the “HER2-low” subgroup has significantly changed how clinicians and researchers view HER2 biology. Once categorized under HER2-negative disease, HER2-low tumors — typically defined as IHC 1+ or IHC 2+/ISH– — are now seen as actionable, particularly in breast cancer, following the breakthrough of antibody–drug conjugates...
0 Comments 0 Shares 60 Views 0 Reviews
Sponsored
Sponsored
Sponsored